RT Journal Article
SR Electronic
T1 No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.10.20060699
DO 10.1101/2020.04.10.20060699
A1 Matthieu Mahévas
A1 Viet-Thi Tran
A1 Mathilde Roumier
A1 Amélie Chabrol
A1 Romain Paule
A1 Constance Guillaud
A1 Sébastien Gallien
A1 Raphael Lepeule
A1 Tali-Anne Szwebel
A1 Xavier Lescure
A1 Frédéric Schlemmer
A1 Marie Matignon
A1 Medhi Khellaf
A1 Etienne Crickx
A1 Benjamin Terrier
A1 Caroline Morbieu
A1 Paul Legendre
A1 Julien Dang
A1 Yoland Schoindre
A1 Jean-Michel Pawlotski
A1 Marc Michel
A1 Elodie Perrodeau
A1 Nicolas Carlier
A1 Nicolas Roche
A1 Victoire de Lastours
A1 Luc Mouthon
A1 Etienne Audureau
A1 Philippe Ravaud
A1 Bertrand Godeau
A1 Nathalie Costedoat-Chalumeau
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.10.20060699.abstract
AB Background Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies.Methods We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoint was transfer to intensive care unit (ICU) within 7 days from inclusion and/or death from any cause. Analyses were adjusted for confounding factors by inverse probability of treatment weighting.Results This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47–1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13–2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65–2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation.Interpretation These results do not support the use of HCQ in patients hospitalised for documented SARS-CoV-2-positive hypoxic pneumonia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was obtained for this studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from authors upon reasonable request.